Eli Lilly’s Retatrutide Cuts Weight 20.8% Over 80 Weeks in Phase 3 Trial

The significance here is not the weight-loss figure itself but the regulatory path: a BLA filing is now framed for early 2027, which sets the timeline that competitors, payers and manufacturing plans will work back from. The obesity-drug field has effectively become a race of efficacy benchmarks, and a result at this level raises the bar for whatever follows. The open question is whether the filing stays on schedule and how regulators treat a candidate with this mechanism.